Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Drug Profile

Research programme: lung disorder therapeutics - Lung Therapeutics/University of Texas Health Sciences Center at Tyler

Alternative Names: LTI-02; LTI-03; scuPA; Single chain urokinase plasminogen activator

Latest Information Update: 10 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Class Antifibrotics; Plasminogen activator enzymes; Serine endopeptidases
  • Mechanism of Action Fibrinolytic agents; Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lung injury; Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Oct 2014 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route)
  • 28 Oct 2014 Preclinical trials in Acute lung injury in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top